Effect of the dual 5α‐reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia

Study Type – Therapy (RCT) Level of Evidence 1b OBJECTIVE To investigate the effects of dutasteride on serum testosterone level and body mass index (BMI) in men who received medical therapy for benign prostatic hyperplasia (BPH). PATIENTS AND METHODS In all, 120 patients with BPH were randomized to three treatment groups: tamsulosin 0.2 mg/day (α‐blocker group), dutasteride 0.5 mg/day (dutasteride group), or tamsulosin 0.2 mg plus dutasteride 0.5 mg/day (combination group) for 1 year. For all patients the BMI and serum testosterone levels were checked at baseline and after 1 year of treatment. RESULTS Among the evaluable 107 patients, the dutasteride (33) and combination groups (37) had significantly greater increases in serum testosterone level (16.3% and 15%, respectively) than the α‐blocker group (37; 0.3%) after 1 year of treatment (both P